Medication info
Alendmax Plus D Tablet

Alendmax Plus D Tablet

Prescription medicationTabletOral
Ingredient · strength
Sodium Alendronate Trihydrate›91.37mg / 1 tabletCholecalciferol Concentrate Powder›53.33mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
White to light gray rectangular tablet
Packaging
4 tablets/box [4 tablets/PTP×1]
Approval status
Active

MFDS item code 201110502 · Approved 2011.11.30 · Insurance code 643506120

Summary

Main use
Treatment of osteoporosis in postmenopausal women and men
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. Discontinuation should be considered after 3~5 years of treatment in patients at low risk of fracture. Patients who discontinue treatment should be regularly reassessed for fracture risk. Mineral water and other beverages or food, including barley tea, as well as medicines, may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this medicine or at the same time may reduce the absorption of alendronate in the body and decrease its effectiveness. This medicine should be taken as soon as you get up in the morning and swallowed with a sufficient amount of water (170∼230 mL) to help the medicine reach the stomach quickly and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after the first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “Precautions”). Patients with inadequate dietary intake of calcium and vitamin D should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine, taken once weekly, provides a weekly amount equivalent to 400 IU or 800 IU of vitamin D per day. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and then continue taking it regularly once weekly. Do not take 2 tablets on the same day. Use in older adults (65 years and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance less than 35 mL/min) because clinical experience is insufficient.
Child dose
Children and adolescents (under 18 years): The safety and efficacy in children and adolescents have not been established.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women and men

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women and men.

How to take

Adult dose

Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. Discontinuation should be considered after 3~5 years of treatment in patients at low risk of fracture. Patients who discontinue treatment should be regularly reassessed for fracture risk. Mineral water and other beverages or food, including barley tea, as well as medicines, may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this medicine or at the same time may reduce the absorption of alendronate in the body and decrease its effectiveness. This medicine should be taken as soon as you get up in the morning and swallowed with a sufficient amount of water (170∼230 mL) to help the medicine reach the stomach quickly and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after the first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “Precautions”). Patients with inadequate dietary intake of calcium and vitamin D should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine, taken once weekly, provides a weekly amount equivalent to 400 IU or 800 IU of vitamin D per day. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and then continue taking it regularly once weekly. Do not take 2 tablets on the same day. Use in older adults (65 years and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance less than 35 mL/min) because clinical experience is insufficient.

Child dose

Children and adolescents (under 18 years): The safety and efficacy in children and adolescents have not been established.

Precautions

This medication may irritate the upper gastrointestinal mucosa and can cause esophageal adverse reactions such as esophagitis or esophageal ulcer. If you experience symptoms such as difficulty swallowing, pain while swallowing, pain behind the sternum, or heartburn, you should stop taking the medication immediately and consult a doctor. After taking the medication, do not lie down for at least 30 minutes and take it with plenty of water to reduce the risk of esophageal irritation. Patients with conditions that delay esophageal emptying, those unable to sit or stand upright for at least 30 minutes, those allergic to the ingredients of this medication, those with hypocalcemia, and those with certain genetic metabolic problems should not take this medication. Gastrointestinal symptoms such as indigestion, abdominal pain, nausea, diarrhea, constipation, acid reflux, esophagitis, as well as musculoskeletal pain, headaches, and dizziness have been reported. If you experience severe bone, joint, or muscle pain, you should consult a doctor, and if symptoms are severe, you may need to stop taking the medication. This medication may reduce absorption when taken with calcium supplements or antacids, as well as some other medications, so a gap of more than 30 minutes should be allowed between doses. Care should be taken when using this medication with aspirin or non-steroidal anti-inflammatory drugs, as it may increase the risk of gastrointestinal adverse reactions. During pregnancy, the decision to use this medication should be made carefully considering the potential risks to the fetus and mother, and caution is also necessary when breastfeeding. It should not be used in children, and elderly patients or those with significantly reduced kidney function should consult a doctor before use. When taking this medication, it should be taken in the morning with plenty of water before the first food or drink, and do not lie down for 30 minutes after taking it. This medication should be swallowed whole, as chewing or sucking it can cause damage to the esophagus. Rarely, long-term use may lead to fractures in specific areas of the bone, so consult a doctor if abnormal symptoms occur. In the event of overdose, hypocalcemia or gastrointestinal irritation symptoms may appear, and you should visit a medical institution immediately; do not induce vomiting. This medication should be kept out of reach of children, and transferring it to other containers should be avoided.

Side effects

esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, dyspepsia, constipation, diarrhea, flatulence, acid reflux, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, taste disturbance, rash, erythema, anastomotic ulcer, urticaria, angioedema, myalgia, lassitude, asthenia, fever, symptoms of hypocalcemia, peripheral edema, oral pharyngeal ulcer, gastric ulcer, duodenal ulcer, localized jawbone necrosis, joint swelling, low-energy fractures of the femoral head and other bones, itching, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external auditory canal, nasopharyngitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, therefore it should be stored in a tightly sealed container. Keep it at room temperature between 1°C and 30°C, and store it in a dark place to prevent light exposure.

Appearance and packaging

Appearance

White to light gray rectangular tablet

Package unit

4 tablets/box [4 tablets/PTP×1]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.